Get started
Author

Allison Lam

Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
2022 · David T. Teachey, Meenakshi Devidas, et al. · Journal of Clinical Oncology · 159
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
2024 · Robert J. Hayashi, Michelle L. Hermiston, et al. · Blood · 19
Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231
2020 · David T. Teachey, Meenakshi Devidas, et al. · Blood · 10
Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue
2026 · Nadine Goldhammer, Marin Bont, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231
2022 · Robert J. Hayashi, Michelle L. Hermiston, et al. · Blood · 1
Neuroimaging in FDXR-related mitochondriopathy
2026 · Allison Lam, Bryce D. Beutler, et al. · Pediatric Radiology
PDF
Abstract A059: Heterogeneous cell populations in organoid models derived from breast preinvasive and invasive carcinomas after endocrine therapy
2024 · Nadine Goldhammer, Shruti Warhadpande, et al. · Cancer Research
Pcn300 Evaluation of Overall Survival Associated With Change in Dosing of Bortezomib, Melphalan, and Prednisone Regimen in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: a Real-world Study
2019 · M. Mehra, R. Potluri, et al. · Value in Health
Works count: 8
Citation count: 190
H-index: 3
I10-index: 3
Year
Topic
Type